Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Capital Expenditures: 2013-2025

Historic Capital Expenditures for Coherus Oncology (CHRS) over the last 10 years, with Jun 2025 value amounting to -$483.4 million.

  • Coherus Oncology's Capital Expenditures fell 1108.50% to -$483.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$706.5 million, marking a year-over-year decrease of 210.29%. This contributed to the annual value of $286,000 for FY2023, which is 85.97% down from last year.
  • Coherus Oncology's Capital Expenditures amounted to -$483.4 million in Q2 2025, which was down 10,343.70% from $4.7 million recorded in Q1 2025.
  • Coherus Oncology's Capital Expenditures' 5-year high stood at $4.7 million during Q1 2025, with a 5-year trough of -$483.4 million in Q2 2025.
  • For the 3-year period, Coherus Oncology's Capital Expenditures averaged around -$100.9 million, with its median value being $34,000 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 324.14% in 2022, then crashed by 123,667.76% in 2024.
  • Over the past 5 years, Coherus Oncology's Capital Expenditures (Quarterly) stood at $468,000 in 2021, then slumped by 81.41% to $87,000 in 2022, then crashed by 60.92% to $34,000 in 2023, then crashed by 40,100.00% to -$40.0 million in 2024, then plummeted by 1,108.50% to -$483.4 million in 2025.
  • Its Capital Expenditures stands at -$483.4 million for Q2 2025, versus $4.7 million for Q1 2025 and -$40.0 million for Q2 2024.